Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

10.21037/tlcr-22-661

Saved in:

Bibliographic Details
Main Authors:	Ma, Jun, Tan, Sze Huey, Yin, Daniel Xing Cheng, Tran, Nguyen Tuan Anh, San Tan, Gek, Lai, Gillianne Geet Yi, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Rajasekaran, Tanujaa, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel Shao-Weng, Lim, Darren Wan-Teck, Ng, Quan Sing, Tan, Wan Ling
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	AME PUBLISHING COMPANY 2024
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System MUTATIONS AFATINIB NSCLC TKI TECHNOLOGIES AZD9291
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/248897
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.21037/tlcr-22-661